Skip to main content
Raphas Co., Ltd. logo

Raphas Co., Ltd. — Investor Relations & Filings

Ticker · 214260 ISIN · KR7214260002 KO Manufacturing
Filings indexed 330 across all filing types
Latest filing 2026-05-28 Regulatory Filings
Country KR South Korea
Listing KO 214260

About Raphas Co., Ltd.

https://www.raphas.com/

Raphas Co., Ltd. is a biotechnology company specializing in advanced drug delivery systems. The company develops and manufactures biodegradable, dissolving microneedles using its proprietary DEN technology, a transdermal delivery platform. This technology is applied to create patches for a range of cosmetic and therapeutic needs, including anti-aging, wrinkle reduction, whitening, and acne treatment. Raphas commercializes its products through its own cosmetics brand, Acropass, and also offers manufacturing services for custom patch development.

Recent filings

Filing Released Lang Actions
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (알레르기비염 면역치료제 DF19001의 임상 2b/3상 임상시험계획(IND) 승인 신청)
Regulatory Filings Classification · 85% confidence The document is a Korea Exchange (KRX) regulatory disclosure titled “투자판단 관련 주요경영사항” (Material Information for Investment Decision) describing a clinical trial IND approval application and its correction. It is not a full financial report, earnings release, management presentation, or any other specific category but rather a general corporate event announcement filed under exchange rules. Therefore, it falls under the fallback category of Regulatory Filings (RNS).
2026-05-28 Korean
투자판단관련주요경영사항(임상시험계획승인신청) (알레르기비염 면역치료제 DF19001의 임상 2b/3상 임상시험계획(IND) 승인 신청)
Regulatory Filings Classification · 78% confidence The document is a Korean stock exchange disclosure of a material business event (submission of a clinical trial plan for a new drug). It does not contain financial statements, earnings figures, or management discussion of results; it is not an annual or interim report, earnings release, dividend notice, or proxy/solicitation. It is a general regulatory announcement of an operational event, fitting the fallback category Regulatory Filings (RNS).
2026-05-22 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” (Quarterly Report) covering the period January 1 to March 31, 2026 (1st quarter) and contains detailed financial, corporate, and business information for that interim period. It is the full quarterly report itself, not merely an announcement. Therefore, it matches the definition of an Interim / Quarterly Report (Code: IR). Q1 2026
2026-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 92% confidence The document is a “주식등의 대량보유상황보고서(일반)” filed under Korea’s Capital Markets and Financial Investment Business Act, detailing a person’s and related parties’ significant shareholdings, changes in holdings, percentages before and after thresholds, and reasons for the changes. This matches the definition of a Major Shareholding Notification (MRQ).
2026-05-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is a Korean "임원ㆍ주요주주 특정증권등 소유상황보고서" filed with the Securities and Futures Commission and Korea Exchange, detailing personal share ownership and trades by an executive (Jeong Do Hyeon). It reports dates, share counts, ratios, and transaction details—matching an insider share transaction report. This corresponds to the Director’s Dealing category.
2026-05-12 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 96% confidence The document is a regulatory notice entitled "사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고," detailing the appointment and dismissal of an outside director. This clearly corresponds to an announcement of changes in the company's board of directors, fitting the Board/Management Information category (MANG).
2026-03-30 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.